Net loss was RMB92.1 million (US$12.6 million), compared with a net loss of RMB229.8 million in the prior year, representing a decrease of 59.9%. Adjusted net loss was RMB199.3 million (US$27.3 ...

We recently published a list of the 12 Best IPO Stocks to Buy in 2025. In this article, we are going to take a look at where ...

The SEC, investment banks and other stakeholders are increasingly focused on cybersecurity in IPO companies given the potential financial, legal ...

In recent years, a variety of alternative paths to public ownership and trading liquidity have emerged. The reverse merger is among one of the ...

From early-stage to growth-stage, founders and investors save $300+ on tickets for All Stage in Boston on July 15. Offer ...

The IPO market rebounds in 2025 as lower inflation and interest rate cuts drive activity. Explore key trends, top IPOs, and ...

Meanwhile, CoreWeave’s syndicate of 14 IPO advisers had reportedly been aiming for approximately 15 times forward EBIT. So even if recent speculation proves accurate that the price range has moved ...

Hotel101 Global, a subsidiary of DoubleDragon, seeks an IPO on Nasdaq through a SPAC to build condominium hotels. Here are ...

All Stage ticket prices go up! Save $300+ on founder and investor passes before March 31 at 11:59 p.m. PT. Register here.

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

VESPER-2 is a 28-week Phase 2b clinical trial assessing the efficacy and tolerability of different weekly doses of MET-097i with or without titration. The trial enrolled the first participant in March ...

With any financial investment — not just crypto — financial leverage can magnify gains, but it can also magnify and ...